Letters

7. Moharram S. A., Shah K., Khanum F., Rönnstrand L. and Kazi J. U. (2019) The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer Journal 9:5 (Pubmed, Link, Lund University, ResearchGate).

6. Shah K., Moharram S. A. and Kazi J. U. (2018) Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. Clinical Epigenetics 10:83 (Pubmed, Link, Lund University, ResearchGate).

5. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) Protein Kinase C expression is deregulated in chronic lymphocytic leukemia. Leukemia and Lymphoma 54(10): 2288-2290. ( Pubmed, Link, Lund University, ResearchGate, Commentary).

4. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) The basic helix-loop-helix (bHLH) proteins in breast cancer progression. Medical Oncology 30(3): 666 (Pubmed, Link, Lund University, ResearchGate).

3. Kazi J. U., Sun J. and Rönnstrand L. (2013) The presence or absence of IL-3 during long-term culture of Flt3-ITD and c-Kit-D816V expressing Ba/F3 cells influences signaling outcome. Experimental Hematology 41(7): 585-587 (Pubmed, Link, Lund University, ResearchGate).

2. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL). Medical Oncology 30(1):462 (Pubmed, Link, Lund University, ResearchGate).

1. Kabir N. N. and Kazi J. U. (2013) Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance. Medical Oncology 30(1): 448 (Pubmed, Link, Lund University, ResearchGate).